ArticleEULAR rheumatology open2026
Early progression of systemic sclerosis: a longitudinal cohort study on disease evolution and microvascular changes.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Available Biomarkers for Personalized Prognostication in Early and Very Early Systemic Sclerosis: A Narrative Review of the Current Literature.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate the time from early-stage systemic sclerosis (SSc), to the onset of significant disease progression. A secondary objective was to identify early clinical features most strongly associated with disease progression. Additionally, the study examined the course of microvascular changes over time. Methods: In this prospective longitudinal cohort study (Hit Hard and Early trial, 3 years open label follow-up), we included patients who met the adjusted Very Early Diagnosis of Systemic Sclerosis criteria, with puffy fingers for less than 3 years. Disease progression was defined as skin or organ involvement. Microvascular changes were tracked through serial nailfold videocapillaroscopy, and Kaplan-Meier estimates were used to analyse time to disease progression. Baseline predictors of progression were explored with univariate logistic regression. Results: Thirty patients were included, 70% female, with a median duration of puffy fingers of 5.5 months. Anticentromere antibodies were present in 73%, and 75% showed an active nailfold capillaroscopy pattern at baseline. Over 3 years, 43% (95% CI: 25.6%-61.2%) developed clinically significant disease progression, predominantly manifesting as pitting scars, digital ulcers, and/or skin thickening. Mean capillary density declined over time, and 55% of patients with an early SSc capillaroscopy pattern progressed to an active or late pattern within 24 months. Conclusions: A large proportion of patients showed clinically relevant disease progression within 3 years. In spite of the limited sample size, the strong association between anti-ribonucleoprotein (anti-RNP) antibodies and disease progression underlines the prognostic value of this biomarker. Frequent and standardised nailfold capillaroscopy imaging provided insights into microvascular changes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.